DIKUL - logo
(UL)
  • VDR genotype and response to etidronate therapy in late postmenopausal women
    Marc, Janja ...
    Twenty-four late postemnopausal women with osteoporosis were studied. The patients were separated in three subgroups according to the BsmI polymorphism of the vitamin D receptor (VDR) gene BB (n=8), ... Bb (n=10) and bb (n=6). They did not differ in age (mean ages were 66,0 years and 63.9 years respectively), zears after menopause (18,7 years, 18.1 years and 18.4 years) or body weight (64.9 kg, 65.3 kg and 63.8 kg), the variables known to be associated with bone mineral density (BMD). The results show that the responseto antiresorptive biphosphonate therapy in combination with the calcium supplementation is modified by VDR genotype. The lumbar spine BMD increased significantly faster in the BB and Bb groups (7.3% and 7.0%, respectively) compared with the bb group (2.5%) during 1 year of cyclic etidronate therapy (400 mg/day) and calcium supplementation (1000 mg/day). Thebiochemical marker of bone resorption (urinary hydroxyproline excretion) as well as the bone formation marker (serum levels of osteoalcin) decreased during the treatment. With respect to VDR gernotype, a significantly higher decrease in osteocalcin level was observed in bb as compared with BB subjects. We conclude that the VDR genotype is involved in an individual's response to cyclic etidronate therapy with calcium supplementation.
    Source: Osteoporosis international. - ISSN 0937-941X (Vol. 10, no. 4, suppl., 1999, str. 303-306)
    Type of material - article, component part ; adult, serious
    Publish date - 1999
    Language - english
    COBISS.SI-ID - 572529

source: Osteoporosis international. - ISSN 0937-941X (Vol. 10, no. 4, suppl., 1999, str. 303-306)

loading ...
loading ...
loading ...